CD47 and acute myeloid leukemia: Therapeutic antibodies against CD47 selectively eliminated acute myeloid leukemia [6], lymphoblastic leukemia [7], pancreatic cancer stem cells [3], breast cancer [8], and hepatocellular carcinoma [4] through inducing the phagocytosis of cancer cells, directly inducing apoptosis, or sensitizing cancer cells to chemotherapy.